Inventor · disambiguated record
Anne Goubier
Also filed as: GOUBIER ANNE
21 granted patents·4 pending applications·38 citations·filing 2012–2025
93Inventor score
Files withTUSK THERAPEUTICS LTD14Black Belt Therapeutics Ltd8ESQUERRE MICHAEL1GENTICEL1MERCHIERS PASCAL1
Top patents by PatentIndex Score
25 records- 0197US10752691B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 25, 2020·12 cites·29 claims
- 0296US10745485B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 18, 2020·11 cites·29 claims
- 0396US10738125B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Aug 11, 2020·11 cites·25 claims
- 0485US11787866B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 17, 2023·1 cites·11 claims
- 0585US11697688B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jul 11, 2023·1 cites·26 claims
- 0676US11236173B2CD38 antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Feb 1, 2022·1 cites·17 claims
- 0775US11873341B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Jan 16, 2024·0 cites·22 claims
- 0875US11851494B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Dec 26, 2023·0 cites·27 claims
- 0975US11542338B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Jan 3, 2023·1 cites·18 claims
- 1075US2025367286A1Cd38 modulating antibody agentsMERCHIERS PASCAL·Filed 2025·Application pending·0 cites
- 1174US11814434B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Nov 14, 2023·0 cites·26 claims
- 1274US11802161B2Anti-CD25 for tumour specific cell depletionTUSK THERAPEUTICS LTD·Filed 2019·Granted Oct 31, 2023·0 cites·26 claims
- 1374US11802160B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2020·Granted Oct 31, 2023·0 cites·10 claims
- 1473US11919960B2Anti-CD25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2019·Granted Mar 5, 2024·0 cites·28 claims
- 1572US2024092928A1Cd38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2023·Application pending·0 cites
- 1669US12162949B2CD38 antibodyBlack Belt Therapeutics Ltd·Filed 2022·Granted Dec 10, 2024·0 cites·12 claims
- 1765US2024309101A1Anti-cd25 antibody agentsTUSK THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1864US12343394B2CD38 modulating antibody agentsBlack Belt Therapeutics Ltd·Filed 2018·Granted Jul 1, 2025·0 cites·19 claims
- 1963US12304964B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2022·Granted May 20, 2025·0 cites·16 claims
- 2063US12161717B2CD38 modulating antibody agentsBlack Belt Therapeutics Ltd·Filed 2018·Granted Dec 10, 2024·0 cites·18 claims
- 2159US11780930B2CD38 modulating antibodyBlack Belt Therapeutics Ltd·Filed 2018·Granted Oct 10, 2023·0 cites·17 claims
- 2249US11879014B2Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibodyTUSK THERAPEUTICS LTD·Filed 2018·Granted Jan 23, 2024·0 cites·16 claims
- 2338US2020283535A1Compounds and methods for tumour-specific cell depletionTUSK THERAPEUTICS LTD·Filed 2018·Application pending·0 cites
- 2437US9827302B2HPV/CyaA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disordersGENTICEL·Filed 2013·Granted Nov 28, 2017·0 cites·16 claims
- 2523US9902947B2CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responsesESQUERRE MICHAEL·Filed 2012·Granted Feb 27, 2018·0 cites·29 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →